Related Experiment Video
Updated: Oct 18, 2025
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
32.6K
Intracameral sustained release bimatoprost implants (Durysta)
Portia E Sirinek1, Michael M Lin1
1Glaucoma Service, Massachusetts Eye and Ear, Boston, MA, USA.
Seminars in Ophthalmology
|September 29, 2021
Summary
Sustained release bimatoprost implants offer an alternative to daily glaucoma eye drops, maintaining intraocular pressure control with fewer side effects. Further research is needed to understand long-term safety and efficacy.
Area of Science:
- Ophthalmology
- Drug Delivery Systems
Background:
- Glaucoma management is challenged by medication adherence.
- Sustained release drug delivery offers a potential solution.
- Durysta is the only FDA-approved sustained release intracameral treatment for glaucoma.
Purpose of the Study:
- To review the only FDA-approved sustained release intracameral glaucoma treatment, Durysta.
- To discuss the efficacy and safety of bimatoprost sustained release (BimSR) implants.
- To explore potential mechanisms for sustained intraocular pressure (IOP) lowering.
Main Methods:
- Review of clinical trials and studies on Durysta (BimSR).
- Analysis of IOP control compared to topical treatments.
- Evaluation of safety concerns, particularly corneal endothelial cell loss.
Main Results:
- BimSR implants provide comparable IOP control to topical eyedrops.
- Advantages include improved adherence, reduced side effects, and decreased treatment burden.
- Extended IOP lowering observed even after medication delivery, with hypothesized mechanisms involving extracellular matrix reorganization and reduced episcleral venous pressure.
Conclusions:
- Durysta offers a promising alternative for glaucoma care.
- Corneal endothelial cell loss is a significant safety concern, especially with repeat administration.
- Further research is required to optimize dosing and understand long-term safety and efficacy.
Related Concept Videos
01:22Drug Delivery: Miscellaneous Routes
544
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
544
01:28Angle Closure Glaucoma: Treatment
889
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
889
01:27Open Angle Glaucoma: Treatment
755
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
755